p95HER2-TCB

N/A

Report date: 2026/03/19 16:57:22

Base Information

Drug Namep95HER2-TCB
Drug Alias NameT cell bispecific antibody (Roche/Vall d'Hebron University Hospital/Memorial Sloan Kettering Cancer Center/Universitat Autonoma de Barcelona)Anti-CD3/anti-p95HER2 bispecific T-cell engager (Roche/Vall d'Hebron University Hospital/Memorial Sloan Kettering Cancer Center/Universitat Autonoma de Barcelona)
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibodyBiologics > T cell engagers
Mechanisms of ActionReceptor protein-tyrosine kinase erbB-2 modulatorsT cell surface glycoprotein CD3 modulators
TargetsT cell surface glycoprotein CD3Receptor protein-tyrosine kinase erbB-2
Therapy Area/IndicationsBreast Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesEurope
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesRoche Holding Ltd
China Registration ClassN/A

Develop Information

Active CompaniesHospital Universitari Vall d'HebronUniversitat Autonoma De BarcelonaRoche Holding Ltd +[4] 
Inactive CompaniesN/A
Active IndicationsBreast Neoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A